Form 8-K - Current report:
SEC Accession No. 0001104659-25-015658
Filing Date
2025-02-20
Accepted
2025-02-20 16:05:21
Documents
17
Period of Report
2025-02-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm253570d16_8k.htm   iXBRL 8-K 36079
2 EXHIBIT 1.1 tm253570d16_ex1-1.htm EX-1.1 126450
3 EXHIBIT 4.2 tm253570d16_ex4-2.htm EX-4.2 152831
4 EXHIBIT 99.1 tm253570d16_ex99-1.htm EX-99.1 13383
8 GRAPHIC tm253570d16_ex99-1img001.jpg GRAPHIC 9885
  Complete submission text file 0001104659-25-015658.txt   587408

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rsls-20250215.xsd EX-101.SCH 3048
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rsls-20250215_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rsls-20250215_pre.xml EX-101.PRE 22381
19 EXTRACTED XBRL INSTANCE DOCUMENT tm253570d16_8k_htm.xml XML 3572
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37897 | Film No.: 25645256
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)